dailymail  


GSK to buy rare cancer drug developer IDRx for up to £1bn

 GSK will pay $1bn upfront to acquire the Massachussetts-based company IDRx is developing  ...View More

  Contact Us
  Follow Us
  About

Read the latest local and international news from trusted sources in one place.